Yarrow Bioscience closes VYNE Therapeutics merger as YB-101 enters Phase 2 trial in Graves’ disease
Yarrow Bioscience starts Phase 2 dosing of YB-101 after its VYNE merger, testing a targeted approach to Graves’ disease and thyroid eye disease.
Pharma & Biotech